All updated as on -
The global market for insulin sensitizers is expected to grow from US$15.09 billion in 2023 to US$21.99 billion in 2030, representing a CAGR of 6.5% between 2023 and 2030.
Insulin sensitizers are a type of medication that improves the body's sensitivity to insulin. They function by either raising the amount of insulin receptors on cells or improving the sensitivity of existing insulin receptors. In persons with type 2 diabetes, this aids in controlling blood sugar levels. The rising incidence of type 2 diabetes is a key factor behind the expansion of the insulin sensitizers market. More than 422 million people currently have diabetes, and that number is anticipated to climb to 642 million by 2040, as reported by the World Health Organisation.
An in-depth analysis compiled to provide the most recent understanding of important aspects of the Insulin Sensitizers industry. In order to help businesses strategize effectively, the research seeks to provide a complete outline of the shifting trends, growth scenarios, and market development activities. Manufacturers of Insulin Sensitizers need to anticipate consumer demand and capitalise on new technological developments to ensure their business continues to grow profitably and sustainably. The Insulin Sensitizers Industry Report ensures that you will have more up-to-date information than your rivals. This study provides you with a leading product, submarkets, revenue size, and forecast for 2030 in the Insulin Sensitizers market through the use of structured tables and figures. It also categorises both new entrants and established players in the market.
The insulin sensitizers market is growing due in large part to the increasing incidence of diabetes. Commonly used in the treatment of type 2 diabetes, insulin sensitizers increase the body's responsiveness to insulin and help keep blood sugar levels stable. Having extra weight increases your chances of developing insulin resistance and then developing type 2 diabetes. The global obesity epidemic has increased the demand for efficient insulin sensitizers to treat metabolic illnesses like insulin resistance.
Due to changes in lifestyle, urbanisation, and nutritional preferences, diabetes is becoming increasingly common in emerging economies. Manufacturers of insulin sensitizers should expect substantial growth in these areas due to rising demand for efficient diabetes care options. The healthcare sector is beginning to embrace the idea of personalised medicine. Treatment strategies for diabetes can be individualised depending on a patient's genetic makeup, lifestyle choices, and metabolic profile, and insulin sensitizers can play a role in this process. By taking this route, we can potentially create specific insulin sensitizers and diagnostic tools to go along with them. To maintain optimal glycemic control, insulin sensitizers are commonly used in conjunction with other antidiabetic drugs including insulin and oral hypoglycemic agents. Insulin sensitizers and other medicines in novel combination therapy have enormous commercial potential. Synergistic effects and the ability to treat numerous manifestations of insulin resistance are two reasons why patients may benefit from receiving treatment in a combination setting.
Report Coverage
Global Insulin Sensitizers research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Insulin Sensitizers report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Insulin Sensitizers competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Insulin Sensitizers market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Insulin Sensitizers market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Insulin Sensitizers market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Insulin Sensitizers market based on the below-mentioned segments:
Global Insulin Sensitizers Market, By Type
Thiazolidinediones (TZDs)
Biguanides
Incretin-based therapies
Others
Global Insulin Sensitizers market, By Indication
Type 2 Diabetes
Prediabetes
Polycystic Ovary Syndrome (PCOS)
Global Insulin Sensitizers Market, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Insulin Sensitizers market, Regional Analysis
Insulin sensitizers are a type of medication that improves the body's sensitivity to insulin. They function by either raising the amount of insulin receptors on cells or improving the sensitivity of existing insulin receptors. In persons with type 2 diabetes, this aids in controlling blood sugar levels. The rising incidence of type 2 diabetes is a key factor behind the expansion of the insulin sensitizers market. More than 422 million people currently have diabetes, and that number is anticipated to climb to 642 million by 2040, as reported by the World Health Organisation.
An in-depth analysis compiled to provide the most recent understanding of important aspects of the Insulin Sensitizers industry. In order to help businesses strategize effectively, the research seeks to provide a complete outline of the shifting trends, growth scenarios, and market development activities. Manufacturers of Insulin Sensitizers need to anticipate consumer demand and capitalise on new technological developments to ensure their business continues to grow profitably and sustainably. The Insulin Sensitizers Industry Report ensures that you will have more up-to-date information than your rivals. This study provides you with a leading product, submarkets, revenue size, and forecast for 2030 in the Insulin Sensitizers market through the use of structured tables and figures. It also categorises both new entrants and established players in the market.
The insulin sensitizers market is growing due in large part to the increasing incidence of diabetes. Commonly used in the treatment of type 2 diabetes, insulin sensitizers increase the body's responsiveness to insulin and help keep blood sugar levels stable. Having extra weight increases your chances of developing insulin resistance and then developing type 2 diabetes. The global obesity epidemic has increased the demand for efficient insulin sensitizers to treat metabolic illnesses like insulin resistance.
Due to changes in lifestyle, urbanisation, and nutritional preferences, diabetes is becoming increasingly common in emerging economies. Manufacturers of insulin sensitizers should expect substantial growth in these areas due to rising demand for efficient diabetes care options. The healthcare sector is beginning to embrace the idea of personalised medicine. Treatment strategies for diabetes can be individualised depending on a patient's genetic makeup, lifestyle choices, and metabolic profile, and insulin sensitizers can play a role in this process. By taking this route, we can potentially create specific insulin sensitizers and diagnostic tools to go along with them. To maintain optimal glycemic control, insulin sensitizers are commonly used in conjunction with other antidiabetic drugs including insulin and oral hypoglycemic agents. Insulin sensitizers and other medicines in novel combination therapy have enormous commercial potential. Synergistic effects and the ability to treat numerous manifestations of insulin resistance are two reasons why patients may benefit from receiving treatment in a combination setting.
Report Coverage
Global Insulin Sensitizers research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Insulin Sensitizers report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Insulin Sensitizers competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Insulin Sensitizers market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Insulin Sensitizers Market from 2021 to 2030.
- Market Forecast for Insulin Sensitizers Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Insulin Sensitizers competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Insulin Sensitizers
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Insulin Sensitizers market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Insulin Sensitizers market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical
Primary Target Market
- Market Players of Insulin Sensitizers
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Insulin Sensitizers market based on the below-mentioned segments:
Global Insulin Sensitizers Market, By Type
Thiazolidinediones (TZDs)
Biguanides
Incretin-based therapies
Others
Global Insulin Sensitizers market, By Indication
Type 2 Diabetes
Prediabetes
Polycystic Ovary Syndrome (PCOS)
Global Insulin Sensitizers Market, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Insulin Sensitizers market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive insulin sensitizers market market research and competitor analysis for your business to help you develop more profound insights into the insulin sensitizers market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the insulin sensitizers market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.